BIIB — BIOGEN INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 875045 ·
Last close
$227.60
Market Cap
$33.63B
52W High
$229.19
52W Low
$135.39
ADV30
843,537
Next earnings
2026-10-28
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 2,477,800,000 | 1,816,800,000 | 459,800,000 | 319,500,000 | 29,483,100,000 | 3,382,700,000 | 10,831,400,000 |
| Dec 2025 | 2,279,400,000 | 1,783,900,000 | 385,500,000 | -48,900,000 | 29,439,500,000 | 3,008,500,000 | 11,182,700,000 |
| Sep 2025 | 2,534,700,000 | 1,860,300,000 | 606,500,000 | 466,500,000 | 29,207,500,000 | 3,862,800,000 | 11,000,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$2,878,800,000
Investing CF
$-5,315,500,000
Financing CF
$985,000,000
CapEx
$-388,800,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$5.65
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$20,969,700,000
Inventory
$2,384,300,000
Receivables
$2,398,400,000
ST Investments
$0
EBIT TTM
$1,296,200,000
Pretax Income TTM
$1,011,400,000
Interest Exp TTM
$284,800,000
Analysts
31
Yahoo Snapshot (yfinance, live)
Total Revenue
$10,027,899,904
EBITDA
$3,359,200,000
Free Cash Flow
$1,266,987,520
Enterprise Value
$39,154,880,512
Total Cash
$1,284,999,936
Total Debt
$8,355,100,160
Shares Out
147,753,998
Trailing EPS
$5.62
Book Value
$127.61
ROE
4.6%
ROA
5.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 9,890,600,000 | 2,469,000,000 | 1,292,900,000 | 29,439,500,000 | 11,182,700,000 | 18,256,800,000 | 2,204,600,000 |
| Dec 2024 | 9,675,900,000 | 2,280,400,000 | 1,632,200,000 | 28,049,300,000 | 11,333,300,000 | 16,716,000,000 | 2,875,500,000 |
| Dec 2023 | 9,835,600,000 | 1,847,700,000 | 1,161,100,000 | 26,844,800,000 | 12,045,400,000 | 14,799,400,000 | 1,547,200,000 |
| Dec 2022 | 10,173,400,000 | 2,901,900,000 | 3,046,900,000 | 24,554,100,000 | 11,165,700,000 | 13,397,900,000 | 1,384,300,000 |
TTM Snapshot
Revenues TTM
$9,935,600,000
NetIncome TTM
$1,695,600,000
OpCashFlow TTM
$0
Assets (Latest)
$29,439,500,000
Forward EPS
$16.54
Max Pain — expiry 2026-10-02 (volume-derived — Yahoo OI feed degraded)
max pain strike: $220.00 · spot: $227.60 · call volume: 1,223 · put volume: 411
Expected Move to 2026-10-02:
±$8.28
(3.64%) —
implied range
$219.32 –
$235.88
· ATM straddle on $227.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RVMD | Revolution Medicines, Inc. | $43.93B | $204.97 | — |
| BNTX | BioNTech SE | $24.75B | $98.52 | — |
| ARGX | ARGENX SE | $59.67B | $959.49 | — |
| EXEL | EXELIXIS, INC. | $14.41B | $58.16 | — |
| MRNA | Moderna, Inc. | $79.40B | $198.88 | — |
News headlines (Yahoo Finance, 1h cache)
Biogen (NASDAQ:BIIB) Q2 Earnings: Leading The Therapeutics Pack
2026-09-25 22:56 · Yahoo
How Investors May Respond To Biogen (BIIB) Advancing At-Home LEQEMBI Pen And Kidney Disease Data
2026-09-23 14:17 · Yahoo
Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-M
2026-09-17 20:15 · Yahoo
Is Biogen Stock Outperforming the S&P 500?
2026-09-16 10:36 · Yahoo
Biogen (BIIB) and AbbVie (ABBV) Get Wolfe Upgrades—Which Pharma Stock Has More Upside?
2026-09-15 19:47 · Yahoo
Hummingbird Bioscience Appoints Dr. James Garner as President
2026-09-15 09:00 · Yahoo
Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience
2026-09-15 04:02 · Yahoo
Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology
2026-09-12 21:01 · Yahoo
Vault CRM Extends Market Leadershipas Another Top 20 Biopharma Chooses Veeva
2026-09-23 11:03 · Yahoo
Register Now: Limited Seating Remains for HMG Strategy’s Sept. 10 Boston C-Level Technology Leadership Summit
2026-09-08 14:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.